DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Fundamental Analysis
USA - NASDAQ:DBVT - US23306J2006 - ADR
13.97 USD
-0.07 (-0.5%)
Overall DBVT gets a fundamental rating of 2 out of 10. We evaluated DBVT against 535 industry peers in the Biotechnology industry. DBVT has a bad profitability rating. Also its financial health evaluation is rather negative. DBVT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
DBVT had negative earnings in the past year.
DBVT had a negative operating cash flow in the past year.
In the past 5 years DBVT always reported negative net income.
In the past 5 years DBVT always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of DBVT (-85.56%) is worse than 71.72% of its industry peers.
The Return On Equity of DBVT (-142.22%) is worse than 62.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.56% | ||
| ROE | -142.22% | ||
| ROIC | N/A |
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 91.34%, DBVT belongs to the best of the industry, outperforming 92.13% of the companies in the same industry.
DBVT's Gross Margin has declined in the last couple of years.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
2. Health
2.1 Basic Checks
DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DBVT has been increased compared to 1 year ago.
DBVT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DBVT is higher compared to a year ago.
2.2 Solvency
DBVT has an Altman-Z score of 0.51. This is a bad value and indicates that DBVT is not financially healthy and even has some risk of bankruptcy.
DBVT has a better Altman-Z score (0.51) than 61.24% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that DBVT is not too dependend on debt financing.
DBVT's Debt to Equity ratio of 0.08 is on the low side compared to the rest of the industry. DBVT is outperformed by 62.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.51 |
ROIC/WACCN/A
WACC8.08%
2.3 Liquidity
A Current Ratio of 2.45 indicates that DBVT has no problem at all paying its short term obligations.
The Current ratio of DBVT (2.45) is worse than 69.85% of its industry peers.
DBVT has a Quick Ratio of 2.45. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.45, DBVT is not doing good in the industry: 67.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.45 |
3. Growth
3.1 Past
The earnings per share for DBVT have decreased strongly by -22.83% in the last year.
The Revenue for DBVT has decreased by -72.49% in the past year. This is quite bad
DBVT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.35% yearly.
EPS 1Y (TTM)-22.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
Revenue 1Y (TTM)-72.49%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%26.18%
3.2 Future
Based on estimates for the next years, DBVT will show a very strong growth in Earnings Per Share. The EPS will grow by 23.50% on average per year.
The Revenue is expected to grow by 146.91% on average over the next years. This is a very strong growth
EPS Next Y1.69%
EPS Next 2Y37.64%
EPS Next 3Y23.5%
EPS Next 5YN/A
Revenue Next Year2930.57%
Revenue Next 2Y1762.26%
Revenue Next 3Y277.96%
Revenue Next 5Y146.91%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DBVT. In the last year negative earnings were reported.
Also next year DBVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DBVT's earnings are expected to grow with 23.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.64%
EPS Next 3Y23.5%
5. Dividend
5.1 Amount
No dividends for DBVT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:DBVT (11/7/2025, 8:00:01 PM)
13.97
-0.07 (-0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners53.95%
Inst Owner Change-3.57%
Ins Owners0.06%
Ins Owner Change-0.29%
Market Cap502.20M
Revenue(TTM)3.80M
Net Income(TTM)-122.55M
Analysts80
Price Target17.25 (23.48%)
Short Float %0.09%
Short Ratio0.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34.07%
PT rev (3m)33.02%
EPS NQ rev (1m)0.04%
EPS NQ rev (3m)-21.09%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-13.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 100.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.44 | ||
| P/tB | 4.44 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.89
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-3.22
FCFYN/A
OCF(TTM)-3.21
OCFYN/A
SpS0.14
BVpS3.15
TBVpS3.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.56% | ||
| ROE | -142.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.34% | ||
| FCFM | N/A |
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score2
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.61% | ||
| Cap/Sales | 8.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.45 | ||
| Altman-Z | 0.51 |
F-Score2
WACC8.08%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
EPS Next Y1.69%
EPS Next 2Y37.64%
EPS Next 3Y23.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-72.49%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%26.18%
Revenue Next Year2930.57%
Revenue Next 2Y1762.26%
Revenue Next 3Y277.96%
Revenue Next 5Y146.91%
EBIT growth 1Y-31.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.07%
EBIT Next 3Y16.69%
EBIT Next 5YN/A
FCF growth 1Y0.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A
DBV TECHNOLOGIES SA-SPON ADR / DBVT FAQ
Can you provide the ChartMill fundamental rating for DBV TECHNOLOGIES SA-SPON ADR?
ChartMill assigns a fundamental rating of 2 / 10 to DBVT.
Can you provide the valuation status for DBV TECHNOLOGIES SA-SPON ADR?
ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA-SPON ADR (DBVT). This can be considered as Overvalued.
Can you provide the profitability details for DBV TECHNOLOGIES SA-SPON ADR?
DBV TECHNOLOGIES SA-SPON ADR (DBVT) has a profitability rating of 1 / 10.
Can you provide the financial health for DBVT stock?
The financial health rating of DBV TECHNOLOGIES SA-SPON ADR (DBVT) is 3 / 10.